Abstract 2419: A phase Ib-IIa study evaluating the nanopharmaceutical CRLX101 in combination with bevacizumab in the treatment of patients (pts.) with advanced renal cell carcinoma.

Phase Ib trial of a targeted TLR9 CpG immunomodulator (CPG 7909) in advanced renal cell carcinoma (RCC)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.4644 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 4644-4644 ◽

Cited By ~ 1

Author(s):

J. A. Thompson ◽

T. Kuzel ◽

R. Bukowski ◽

F. Masciari ◽

T. Schmalbach

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

A single arm phase Ib study of RAD001 and sunitinib in patients with advanced renal cell carcinoma (RCC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.e15034 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. e15034-e15034

Author(s):

J. D. Turnbull ◽

A. J. Armstrong ◽

K. Morris ◽

S. E. Yenser Wood ◽

S. Voyles ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Phase Ib trial of a targeted TLR9 CpG immunomodulator (CPG 7909) in advanced renal cell carcinoma (RCC)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.4644 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 4644-4644 ◽

Cited By ~ 9

Author(s):

J. A. Thompson ◽

T. Kuzel ◽

R. Bukowski ◽

F. Masciari ◽

T. Schmalbach

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2013.11.020 ◽

2014 ◽

Vol 12 (4) ◽

pp. 241-250 ◽

Cited By ~ 17

Author(s):

Rhonda L. Bitting ◽

Patrick Healy ◽

Patricia A. Creel ◽

James Turnbull ◽

Karla Morris ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Mtor Inhibition ◽

719P Correlative serum biomarker analyses: Lenvatinib (LEN) plus pembrolizumab (PEMBRO) in a phase Ib/II trial in advanced renal cell carcinoma (RCC)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.791 ◽

2020 ◽

Vol 31 ◽

pp. S564-S565

Author(s):

C-H. Lee ◽

Y. Adachi ◽

H. Ikezawa ◽

S.D. Li ◽

Y. Funahashi ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Serum Biomarker ◽

A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3‐Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma

The Oncologist ◽

10.1634/theoncologist.2016-0145 ◽

2016 ◽

Vol 21 (7) ◽

pp. 787 ◽

Cited By ~ 45

Author(s):

Maria I. Carlo ◽

Ana M. Molina ◽

Yulia Lakhman ◽

Sujata Patil ◽

Kaitlin Woo ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Mammalian Target Of Rapamycin ◽

Target Of Rapamycin ◽

Phosphatidylinositol 3 Kinase ◽

Dual Inhibitor ◽

Phase Ib ◽

Phosphatidylinositol 3

Phase Ib study (COSMIC-021) of cabozantinib in combination with atezolizumab: Results of the dose escalation stage in patients (pts) with treatment-naïve advanced renal cell carcinoma (RCC)

Annals of Oncology ◽

10.1093/annonc/mdy283.081 ◽

2018 ◽

Vol 29 ◽

pp. viii308 ◽

Cited By ~ 4

Author(s):

N. Agarwal ◽

U. Vaishampayan ◽

M. Green ◽

F. di Nucci ◽

P.-Y. Chang ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Dose Escalation ◽

Renal Cell ◽

Phase Ib ◽

Treatment Naïve

Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma

Journal for ImmunoTherapy of Cancer ◽

10.1186/2051-1426-3-s2-p353 ◽

2015 ◽

Vol 3 (S2) ◽

Cited By ~ 16

Author(s):

Michael B Atkins ◽

Shilpa Gupta ◽

Toni K Choueiri ◽

David F McDermott ◽

Igor Puzanov ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Dose Finding ◽

Phase Ib ◽

Finding Study ◽

Treatment Naïve ◽

Dose Finding Study

Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial

European Journal of Cancer ◽

10.1016/j.ejca.2020.12.009 ◽

2021 ◽

Vol 145 ◽

pp. 1-10

Author(s):

Michael B. Atkins ◽

Elizabeth R. Plimack ◽

Igor Puzanov ◽

Mayer N. Fishman ◽

David F. McDermott ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Efficacy And Safety ◽

Phase Ib ◽

Term Efficacy

First-line (1L) or second-line (2L) avelumab monotherapy in patients (pts) with advanced renal cell carcinoma (aRCC) enrolled in the phase Ib JAVELIN solid tumor trial

Annals of Oncology ◽

10.1093/annonc/mdy283.086 ◽

2018 ◽

Vol 29 ◽

pp. viii310-viii311 ◽

Cited By ~ 1

Author(s):

U.N. Vaishampayan ◽

P. Schöffski ◽

A. Ravaud ◽

C. Borel ◽

T. Song ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Solid Tumor ◽

Renal Cell ◽

Second Line ◽

First Line ◽